×
About 465 results

ALLMedicine™ Primary Pulmonary Hypertension Center

Research & Reviews  133 results

Endothelial Cell Dysfunction in Pulmonary Hypertension
https://clinicaltrials.gov/ct2/show/NCT00098072

Mar 10th, 2023 - Introduction: Primary pulmonary hypertension, now known as idiopathic pulmonary arterial hypertension (IPAH), a subgroup of pulmonary arterial hypertension (PAH), is a rare disorder characterized by severe morbidity and high mortality rates. There...

Hemodynamic Effects of a High-Frequency Oscillatory Ventilation Open-Lung Strategy in C...
https://doi.org/10.1097/PCC.0000000000003211
Pediatric Critical Care Medicine : a Journal of the Socie... de Jager P, Curley MAQ et. al.

Mar 7th, 2023 - To study the hemodynamic consequences of an open-lung high-frequency oscillatory ventilation (HFOV) strategy in patients with an underlying cardiac anomaly with or without intracardiac shunt or primary pulmonary hypertension with severe lung injur...

Aerobic Exercise in Patients With Pulmonary Hypertension
https://clinicaltrials.gov/ct2/show/NCT00678821

Mar 6th, 2023 - We propose a randomized trial to determine the safety and effectiveness of aerobic exercise for patients who have primary pulmonary hypertension (PH) or PH secondary to interstitial lung disease (ILD). This project will be the first in a series of...

Pediatric Idiopathic Pulmonary Artery Hypertension
https://emedicine.medscape.com/article/1004828-overview

Feb 7th, 2023 - Practice Essentials Idiopathic pulmonary artery hypertension (IPAH), previously referred to as primary pulmonary hypertension (PPH), is a relatively recently described entity with an unclear etiology. Because many of the symptoms of IPAH are nonsp...

Pediatric Idiopathic Pulmonary Artery Hypertension
https://emedicine.medscape.com/article/1004828-print

Feb 7th, 2023 - Practice Essentials Idiopathic pulmonary artery hypertension (IPAH), previously referred to as primary pulmonary hypertension (PPH), is a relatively recently described entity with an unclear etiology. Because many of the symptoms of IPAH are nonsp...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  32 results

Endothelial Cell Dysfunction in Pulmonary Hypertension
https://clinicaltrials.gov/ct2/show/NCT00098072

Mar 10th, 2023 - Introduction: Primary pulmonary hypertension, now known as idiopathic pulmonary arterial hypertension (IPAH), a subgroup of pulmonary arterial hypertension (PAH), is a rare disorder characterized by severe morbidity and high mortality rates. There...

Aerobic Exercise in Patients With Pulmonary Hypertension
https://clinicaltrials.gov/ct2/show/NCT00678821

Mar 6th, 2023 - We propose a randomized trial to determine the safety and effectiveness of aerobic exercise for patients who have primary pulmonary hypertension (PH) or PH secondary to interstitial lung disease (ILD). This project will be the first in a series of...

A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis
https://clinicaltrials.gov/ct2/show/NCT03889509

Aug 19th, 2022 - A systematic review was conducted to determine the risk/associated factors for pulmonary arterial hypertension in systemic sclerosis, including clinical/disease characteristics, antibody status, test results and biomarkers. The frequency of public...

Comparison of PD1+T Cell Expression in Peripheral Blood for Cardiac Function Prognosis in Patients With Acute MI
https://clinicaltrials.gov/ct2/show/NCT05251987

Feb 23rd, 2022 - Myocardial infarction is a serious common disease in human beings. Although many patients with acute myocardial infarction survive with the improvement of medical technology in recent years, studies have shown that cardiac remodeling caused by myo...

Pulmonary Hypertension in Haemodialysis Patients :Frequency and Risk Factors
https://clinicaltrials.gov/ct2/show/NCT03310229

Jan 20th, 2021 - Primary whose mechanisms are incompletely known, is another vascular disease entity recently described in chronic kidney disease particularly in patients undergoing haemodialysis. It corresponds to 5th subtype of World Symposium on Pulmonary Hyper...

see more →

News  14 results

Peering into My Own Genome
https://www.medpagetoday.com/genetics/genetictesting/53088

Aug 16th, 2015 - I have looked into my genome and seen ... nothing much to worry about. I carry 15 rare genetic variants that have been associated with some form of disease, but I am heterozygous for all of them -- I have one intact copy of the same gene. So I car...

Avenues for protecting against vasculopathy in systemic sclerosis
https://www.mdedge.com/dermatology/article/82448/lupus-connective-tissue-diseases/avenues-protecting-against-vasculopathy/page/0/1

May 19th, 2014 - Endothelin inhibitors Endothelin inhibitors also may play a role in vascular protection. Endothelin is secreted in scleroderma and is a potent vasoconstrictor.

RVH or Posterior MI? Make the Diagnosis
https://www.medscape.com/viewarticle/762321_2

Apr 20th, 2012 - Answer Right ventricular hypertrophy Discussion In this tracing, QRS axis tends to the right axis deviation (RAD), which should make one think of right ventricular hypertrophy (RVH) first. After the RAD, all other diagnostic features of RVH are fo...

Products Liability
https://www.mdedge.com/familymedicine/article/46858/products-liability
Family Practice News;

Dec 29th, 2011 - Question: A woman developed primary pulmonary hypertension (PPH) 4 years after she had stopped using the prescription weight-loss drug, fenfluramine. The drug is known to cause valvular heart lesions as well as PPH.

Commentary - Products Liability
https://www.mdedge.com/psychiatry/article/46857/commentary-products-liability

Dec 29th, 2011 - Question: A woman developed primary pulmonary hypertension (PPH) 4 years after she had stopped using the prescription weight-loss drug, fenfluramine. The drug is known to cause valvular heart lesions as well as PPH.

see more →

Patient Education  2 results see all →